Why the study?
ARNi therapy improves clinical outcomes in HFrEF, but uptake remains modest, potentially in part due to perceived cost considerations of early transition from ACEi or ARB therapy.
Does earlier or de novo transition to sacubitril/valsartan improve cost-effectiveness (ICER per QALY gained) compared with delayed transition or current care in patients with HFrEF?
Does earlier or de novo transition to sacubitril/valsartan improve cost-effectiveness (ICER per QALY gained) compared with delayed transition or current care in patients with HFrEF?
Answers are grounded in this paper and cite their sources.
In the Canadian healthcare system, immediate (de novo) initiation of sacubitril/valsartan in HFrEF is more economically attractive than delaying transition for 3 to 9 months of ACEi/ARB titration.
Background Angiotensin receptor neprilysin inhibitor (ARNi) therapy improves clinical outcomes in patients with heart failure and reduced left ventricular ejection fraction. However, ARNi therapy uptake remains modest, potentially in part due to perceived cost considerations of early transition from angiotensin converting enzyme inhibitor or angiotensin receptor blocker therapy. Methods We constructed a decision-analytic Markov model to assess cost-effectiveness of 3 different ARNi initiation strategies according to timing of initiation: (1) de novo , or immediate initiation at baseline, (2) Early or after 3 months, or (3) Late, or after 9 months. Initiation strategies were compared with (4) current care, with utilization of ARNi derived from a large observational database. Total costs, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER) were estimated over a 5-year time horizon in the base case analysis. Results Current care was associated with the lowest total cost (CAD$26,664) and accrued benefit (3.28 QALYs). The de novo strategy yielded an ICER of $34,727 per QALY gained, whereas Early and Late initiation strategies yielded a less favourable ICER per QALY gained of $35,871 and $40,234, respectively. The model was most sensitive to the cost of ARNi therapy. Conclusion A strategy of de novo ARNi initiation is economically attractive and becomes less favourable as the delay of initiation increases. Our results suggest that ARNi therapy should be initiated as soon as possible for patients with heart failure and reduced left ventricular ejection fraction.
No takes yet. Share an insight, caveat, or question.
Grant et al. (2020) studied Heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan (ARNi) initiation strategies (de novo at baseline, Early at 3 months, or Late at 9 months) vs. Current care (14% initial ARNi uptake after a 9-month optimization period on enalapril 10 mg, βB, and MRA, followed by 0.6% per month uptake) was evaluated on Incremental cost-effectiveness ratio (ICER, in 2018 CAD per QALY gained) over a 5-year time horizon (ICER CAD$34,727 per QALY gained (de novo vs current care)).
Synapse has enriched 10 related papers. Consider them for comparative context: